Site menu

Search by ticker code:
Generic filters


Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

My Top 3 ASX Healthcare Shares

Australia’s population is ageing and companies like Cochlear Limited (ASX: COH) and CSL Limited (ASX: CSL) could stand to benefit.

We’re Getting Older…

About 15% of the population is above 65, and this is projected to grow to more than 20% by 2050. Healthcare shares could be a smart way to take advantage of this trend.

With a growing market for their products, here are three healthcare shares to consider for your portfolio.

Cochlear Ltd (ASX: COH)

Cochlear is a company that provides a range of hearing solutions including cochlear implants and bone conduction implants. These can be life-changing products, as Andrew discussed in great detail in his recent Rask Media article.

Cochlear recorded revenue growth of 11% and net profit growth of 16% in their most recent half-year report, with their net profit margin improving to 18%, from 17%.

While the Cochlear share price has struggled recently, there has been large growth over the five-year and ten-year periods. The share price currently sits around $178, down from its all-time high of about $218 in September 2018.

Cochlear certainly has room to grow and an ageing population will create an increased demand for their product.


CSL is a global biotechnology company and a true Australian success story. The company was founded in Melbourne more than 100 years ago. CSL has a focus on rare and serious diseases and influenza vaccines. This is another company that will see an increase in demand with an ageing population.

The CSL share price has recently been hovering around the $195-$200 range, down from $230 in September 2018. With their half-year report revealing profit growth of 10% and dividend growth of 20%, this could be another prudent long-term investment.

Pro Medicus Ltd (ASX: PME)

If you don’t want to pay $200 for a single share in CSL or COH, Pro Medicus might be another option.

Pro Medicus is a leading provider of radiology information systems (RIS), Picture Archiving and Communication Systems (PACS) and advanced visualisation solutions.

Pro Medicus shares can currently be purchased for around $16-$17 per share. In their most recent half-year report, Pro Medicus revealed an increase in profit after tax of 184% and EBIT margins of 51%. This is a fast-growing healthcare company with share price increases of around 40% in the last six months and more than 100% over the last year.

[ls_content_block id=”14947″ para=”paragraphs”]

Disclaimer: At the time of writing, Max does not own shares in any of the companies mentioned.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Skip to content